BridgeBio Pharma, Inc.
BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 cliniā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$76.83
Price+0.45%
$0.34
1Y
Price
Market Cap
$14.637b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-143.6%
EBITDA Margin-151.4%
Net Profit Margin-91.2%
Free Cash Flow Margin-143.6%
EBITDA Margin-151.4%
Net Profit Margin-91.2%
Free Cash Flow MarginRevenue
$353.780m
+59.4%
1y CAGR+752.2%
3y CAGR+567.0%
5y CAGREarnings
-$797.118m
-48.8%
1y CAGR-21.9%
3y CAGR-12.8%
5y CAGREPS
-$4.19
-45.5%
1y CAGR-12.1%
3y CAGR-3.0%
5y CAGRBook Value
-$1.923b
$998.250m
Assets$2.921b
Liabilities$1.860b
DebtDebt to Assets
186.3%
-2.7x
Debt to EBITDAFree Cash Flow
-$595.212m
-14.1%
1y CAGR-12.3%
3y CAGR-3.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company